アミノ酸代謝異常症治療の世界市場

アミノ酸代謝異常症治療の世界市場は2030年までに9億910万米ドルに達する見込み

2024年に7億3,730万米ドルと推定されるアミノ酸代謝異常症治療の世界市場は、分析期間2024-2030年にCAGR 3.6%で成長し、2030年には9億910万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェニルケトン尿症適応症は、CAGR 4.3%を記録し、分析期間終了時には3億1,750万米ドルに達すると予測されます。メープルシロップ尿症分野の成長率は、分析期間中CAGR 3.5%と推定されます。

米国市場は2億90万米ドルと推定、中国はCAGR6.7%で成長予測

米国のアミノ酸代謝異常症治療市場は、2024年に2億90万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.7%として、2030年までに1億8,290万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.8%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界のアミノ酸代謝異常症治療市場- 主要動向と促進要因まとめ

なぜアミノ酸代謝異常症は世界のヘルスケアの優先課題として急務になっているのか？

アミノ酸代謝異常症は、稀ではあるが生命を脅かす可能性のある遺伝的疾患群であり、体内でのアミノ酸の正常な分解と利用を阻害し、重要な代謝産物の蓄積や欠乏を引き起こします。これらの疾患には、フェニルケトン尿症（PKU）、メープルシロップ尿症（MSUD）、ホモシスチン尿症などがあり、通常、生後早期に発症し、直ちに生涯にわたる医学的管理が必要となります。これらの遺伝性代謝異常症は、個々にはまれであるが、新生児スクリーニングプログラムの進歩や早期診断の重要性の高まりにより、公衆衛生の枠組みにおいて注目されるようになってきています。未治療のアミノ酸障害は、重篤な神経障害、発達遅延、昏睡、あるいは死に至る可能性があるため、早期発見は極めて重要です。多くの国では、新生児スクリーニングがヘルスケアサービスとして義務化され、診断率が劇的に向上し、タイムリーな介入が可能となっています。これらの疾患はしばしば、栄養制限、酵素補充食品療法、アミノ酸補給、場合によっては肝移植を含む特殊な治療プロトコルを必要とします。臨床医やヘルスケア提供者の間で認識が高まるにつれて、特殊な医療食品や精密医療アプローチを含む包括的な治療戦略に対する需要も高まっています。さらに、患者擁護団体や希少疾患ネットワークは、こうした疾患の認知度を高め、治療へのアクセスや調査資金の改善を推進する上で、より大きな役割を果たしています。医療技術革新の重要なフロンティアとして希少疾患への注目度が高まったことで、アミノ酸代謝異常症が脚光を浴びるようになり、罹患者のより効果的で個別化された治療法の開発に向けた世界の取り組みが促されています。

これらの代謝異常の複雑さに対処するために、治療法はどのように進化しているのだろうか？

アミノ酸代謝異常症の治療戦略は、科学的理解の深化、遺伝子スクリーニングの改善、バイオ医薬品の革新によって、過去10年間で大きく進化してきました。従来の治療法は、患者の体が効率的に処理できない特定のアミノ酸を制限したり、除外したりするために、厳格な食事療法を中心に展開されることが多くなりました。例えば、PKU患者はフェニルアラニン制限食を遵守しなければならず、必須栄養素やアミノ酸代替物を強化した医療用食品で補うことが多いです。しかし、食事療法は依然として基本であるが、特に青年や成人では、コンプライアンス、QOL、長期転帰に課題があります。有効性とアドヒアランスを改善するために、研究者や製薬会社は標的薬理学的治療にますます目を向けています。PKUに対するサプロプテリン二塩酸塩のような酵素置換療法や補酵素ベースのアプローチは、残存酵素活性を高め、より自由な食事を可能にするために使用されています。遺伝子治療の進歩もまた有望であり、ウイルスベクター送達システムを通じて根本的な遺伝的欠陥を修正することを目的としており、複数の代謝疾患に対して現在臨床試験が進行中です。さらに、mRNAベースの治療法やCRISPR遺伝子編集も、潜在的な治療法として検討されています。これと並行して、個別化医療栄養市場も拡大しており、患者の代謝プロファイルに基づいたオーダーメイドの製剤が提供されています。こうした開発は、患者や介護者が食事摂取量を追跡し、血中濃度をモニターし、リアルタイムで治療を調整するのに役立つデジタルヘルスツールによって支えられています。この分野の進歩に伴い、患者とその家族双方にとってこれらの疾患が生涯にわたって影響を及ぼすことを認識し、医学的、栄養学的、心理社会的サポートを統合したホリスティックケアモデルが重視されるようになってきています。食事科学、薬物療法、ゲノム医学の融合は、臨床医がアミノ酸代謝障害にどのようにアプローチするかを再定義し、治療をより正確で、利用しやすく、効果的なものにしています。

世界のヘルスケアシステムと市場力学は、治療へのアクセスと開発にどのような影響を与えるのか？

アミノ酸代謝異常症の治療へのアクセスは、国のヘルスケアインフラ、経済資源、規制環境、公衆衛生の優先順位などの影響を受け、地域によって大きく異なります。ヘルスケアシステムが確立されている高所得国では、一般的に普遍的な新生児スクリーニングプログラムを通じて早期スクリーニングと介入が可能であり、患者はしばしば代謝専門のクリニックや助成金による治療を利用することができます。これらの国はまた、臨床研究、医薬品開発、患者支援活動の主要な拠点となっており、新しい治療法や医療栄養ソリューションの迅速な導入に有利な条件を作り出しています。対照的に、多くの中低所得国では、広範なスクリーニングを実施したり、継続的な治療を提供したりするためのインフラや資金が不足しており、診断の遅れ、介入の遅れ、予防可能な合併症につながっています。医療用食品、サプリメント、専門医薬品を含む生涯にわたる治療には高額な費用がかかるため、これらの地域では家族や医療制度にとって大きな負担となっています。さらに、これらの疾患は希少であるため、患者数が少なく、従来の医薬品開発モデルに対する課題となっており、医薬品への投資が複雑になっています。しかし、政府、NGO、製薬企業がパートナーシップを組み、認知度の向上、ヘルスケアプロバイダーの育成、必要不可欠な治療への助成を目指すことで、世界ヘルスへの取り組みがこうしたギャップを埋め始めています。国際的な協力関係はまた、疾病の蔓延、患者の転帰、治療効果を追跡するために不可欠な地域登録の作成も支援しています。規制調和への取り組みは、医薬品承認の迅速化と国境を越えた市場アクセスの拡大に役立っています。精密医療が世界の優先事項となるにつれ、希少代謝疾患を国や国際的な資金調達課題に含める機運が高まっています。全体として、格差は依然として存在するもの、世界のヘルスケアへの取り組みの軌跡は、政策支援、市場革新、世界の協力の組み合わせによって、アミノ酸代謝異常症の治療へのアクセスがより公平になることを示しています。

何がアミノ酸代謝異常症治療市場の成長を促進しているのか？

アミノ酸代謝異常症治療市場の成長は、遺伝子診断の進歩、世界の認知度の向上、治療方法の進化、希少疾患調査への投資の増加など、いくつかの相互関連的な要因によってもたらされます。最も重要な促進要因のひとつは、新生児スクリーニングプログラムの拡大であり、これにより早期診断が改善され、既存の治療法および新たな治療法の両方の対象となる患者層が拡大した。これと並行して、ゲノミクスの技術的飛躍的進歩により、代謝変異のより正確な同定が可能になり、特定の酵素や遺伝子の欠損に合わせた個別化治療の開発が促進されています。先天性代謝異常の有病率の増加も、報告の改善や実際の増加によって、製薬会社の注目を集めており、その多くは現在、酵素補充療法、遺伝子治療プラットフォーム、代謝補因子ソリューションに投資しています。市場独占権の延長や迅速な承認経路といった規制上のインセンティブに支えられた希少疾病用医薬品開発へのシフトは、かつて見過ごされていたこの分野の技術革新を促しています。さらに、医療用栄養ソリューションの急増によって市場が形成されつつあり、各社は特殊なアミノ酸製剤、低タンパク食品、こうした複雑な食事管理を支援するデジタルツールを開発しています。患者擁護団体は、臨床試験への参加を促し、調査のための資金を調達し、償還と公平な治療アクセスを確保するための政策変更を推進することにより、市場拡大においてより大きな役割を果たしています。希少疾患患者特有のニーズに対応するために官民の利害関係者が連携し、アミノ酸代謝異常症の治療状況は急速な進化を遂げています。科学、政策、患者の関与という3つの力が組み合わさることで、今後数年間は市場の成長が維持・加速され、世界中の罹患者の転帰と生活の質が改善される希望がもたらされると期待されています。

セグメント

適応症（フェニルケトン尿症、メープルシロップ尿症、シトルリン血症、ホモシスチン尿症、アルギニノコハク酸尿症）、製品（葉酸、ビタミンB6・B12、アルギニン、チアミン、ベタイン、サプロプテリン、その他製品）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンライン流通チャネル）

調査対象企業の例

• AMINO GmbH
• Alexion Pharmaceuticals
• Astex Pharmaceuticals
• BioMarin Pharmaceutical Inc.
• Camurus AB
• Civentichem LLC
• GlaxoSmithKline plc
• Horizon Therapeutics plc
• Ipsen
• Kyowa Hakko Kirin Co., Ltd.
• Merck KGaA
• Nestle Health Science S.A.
• Pfizer Inc.
• PTC Therapeutics, Inc.
• Recordati S.p.A.
• Sanofi
• Shine Star Biological Engineering Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Amino Acid Metabolism Disorders Treatment Market to Reach US$909.1 Million by 2030

The global market for Amino Acid Metabolism Disorders Treatment estimated at US$737.3 Million in the year 2024, is expected to reach US$909.1 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Phenylketonuria Indication, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$317.5 Million by the end of the analysis period. Growth in the Maple Syrup Urine Disease segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$200.9 Million While China is Forecast to Grow at 6.7% CAGR

The Amino Acid Metabolism Disorders Treatment market in the U.S. is estimated at US$200.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$182.9 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Amino Acid Metabolism Disorders Treatment Market - Key Trends & Drivers Summarized

Why Are Amino Acid Metabolism Disorders Gaining Urgency in Global Healthcare Priorities?

Amino acid metabolism disorders are a group of rare but potentially life-threatening genetic conditions that disrupt the normal breakdown and utilization of amino acids in the body, leading to the accumulation or deficiency of critical metabolites. These disorders, which include phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, and others, typically manifest early in life and require immediate and lifelong medical management. While individually rare, collectively these inherited metabolic disorders are gaining increased attention in public health frameworks due to advancements in neonatal screening programs and the growing emphasis on early diagnosis. Early detection is crucial because untreated amino acid disorders can lead to severe neurological damage, developmental delays, coma, or even death. In many countries, newborn screening has become a mandated healthcare service, dramatically improving diagnosis rates and enabling timely intervention. These disorders often demand specialized treatment protocols involving dietary restrictions, enzyme replacement therapies, amino acid supplementation, or in some cases, liver transplantation. As awareness increases among clinicians and healthcare providers, the demand for comprehensive treatment strategies, including specialized medical foods and precision medicine approaches, is also rising. Furthermore, patient advocacy groups and rare disease networks are playing a larger role in bringing visibility to these disorders and pushing for better therapeutic access and research funding. The heightened focus on rare diseases as a critical frontier in medical innovation has placed amino acid metabolism disorders in the spotlight, prompting global efforts to develop more effective and personalized treatments for affected individuals.

How Are Therapies Evolving to Address the Complexities of These Metabolic Disorders?

Treatment strategies for amino acid metabolism disorders have evolved significantly over the past decade, driven by deeper scientific understanding, improvements in genetic screening, and biopharmaceutical innovations. Traditional management often revolves around strict dietary modifications to limit or exclude specific amino acids that the patient’s body cannot process effectively. For instance, patients with PKU must adhere to a phenylalanine-restricted diet, often supplemented with medical foods fortified with essential nutrients and amino acid substitutes. However, while dietary therapy remains foundational, it presents challenges in compliance, quality of life, and long-term outcomes, particularly in adolescents and adults. To improve efficacy and adherence, researchers and pharmaceutical companies are increasingly turning to targeted pharmacological treatments. Enzyme substitution therapies and cofactor-based approaches, such as sapropterin dihydrochloride for PKU, are being used to enhance residual enzyme activity and allow for more dietary freedom. Advances in gene therapy also hold promise, aiming to correct underlying genetic defects through viral vector delivery systems, with clinical trials currently underway for multiple metabolic conditions. Additionally, mRNA-based therapies and CRISPR gene editing are being explored as potential curative solutions. In parallel, the market for personalized medical nutrition is expanding, offering tailored formulations based on a patient’s metabolic profile. These developments are supported by digital health tools that help patients and caregivers track dietary intake, monitor blood levels, and adjust treatments in real time. As the field progresses, there is a growing emphasis on holistic care models that integrate medical, nutritional, and psychosocial support, recognizing the lifelong impact of these conditions on both patients and their families. The convergence of dietary science, pharmacotherapy, and genomic medicine is redefining how clinicians approach amino acid metabolism disorders, making treatment more precise, accessible, and effective.

How Do Global Healthcare Systems and Market Dynamics Influence Treatment Access and Development?

Access to treatment for amino acid metabolism disorders varies widely across different regions, influenced by national healthcare infrastructure, economic resources, regulatory environments, and public health priorities. In high-income countries with well-established healthcare systems, early screening and intervention are generally available through universal newborn screening programs, and patients often have access to specialized metabolic clinics and subsidized treatments. These nations also serve as major hubs for clinical research, pharmaceutical development, and patient advocacy, creating favorable conditions for the rapid adoption of new therapies and medical nutrition solutions. In contrast, many low- and middle-income countries lack the infrastructure and funding to implement widespread screening or provide ongoing treatment, leading to underdiagnosis, delayed intervention, and preventable complications. The high cost of lifelong therapy, including medical foods, supplements, and specialty drugs, presents a significant burden for families and health systems in these regions. Moreover, the rarity of these disorders complicates pharmaceutical investment, as small patient populations pose challenges to the traditional drug development model. However, global health initiatives are beginning to bridge these gaps, with partnerships between governments, NGOs, and pharmaceutical companies aimed at improving awareness, training healthcare providers, and subsidizing essential treatments. International collaborations also support the creation of regional registries, which are vital for tracking disease prevalence, patient outcomes, and therapy effectiveness. Regulatory harmonization efforts are helping accelerate drug approvals and expand market access across borders. As precision medicine becomes a global priority, there is growing momentum to include rare metabolic disorders in national and international funding agendas. Overall, while disparities remain, the trajectory of global healthcare efforts points toward more equitable access to treatment for amino acid metabolism disorders, driven by a mix of policy support, market innovation, and global collaboration.

What Is Fueling the Growth of the Amino Acid Metabolism Disorders Treatment Market?

The growth in the amino acid metabolism disorders treatment market is driven by several interconnected factors including advances in genetic diagnostics, rising global awareness, evolving treatment modalities, and increasing investment in rare disease research. One of the most significant drivers is the expansion of newborn screening programs, which have improved early diagnosis and widened the eligible patient base for both existing and emerging therapies. Alongside this, technological breakthroughs in genomics have enabled more precise identification of metabolic mutations, fostering the development of personalized treatments tailored to specific enzymatic or genetic deficiencies. The increasing prevalence of inborn errors of metabolism, either through better reporting or actual rise, has also drawn attention from pharmaceutical companies, many of which are now investing in enzyme replacement therapies, gene therapy platforms, and metabolic cofactor solutions. The shift toward orphan drug development, supported by regulatory incentives such as extended market exclusivity and expedited approval pathways, has encouraged innovation in this once-overlooked segment. Additionally, the market is being shaped by a surge in medical nutrition solutions, with companies creating specialized amino acid formulations, low-protein foods, and digital tools to help manage these complex diets. Patient advocacy organizations are playing a larger role in market expansion by driving clinical trial participation, fundraising for research, and pushing for policy changes that ensure reimbursement and equitable treatment access. As public and private stakeholders align to address the unique needs of rare disease patients, the treatment landscape for amino acid metabolism disorders is undergoing rapid evolution. The combined forces of science, policy, and patient engagement are expected to sustain and accelerate market growth in the coming years, offering hope for improved outcomes and quality of life for affected individuals worldwide.

SCOPE OF STUDY:

The report analyzes the Amino Acid Metabolism Disorders Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication, Argininosuccinic Aciduria Indication); Product (Folic Acid, Vitamin B6 & B12, Arginine, Thiamine, Betaine, Sapropterin, Other Products); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AMINO GmbH
• Alexion Pharmaceuticals
• Astex Pharmaceuticals
• BioMarin Pharmaceutical Inc.
• Camurus AB
• Civentichem LLC
• GlaxoSmithKline plc
• Horizon Therapeutics plc
• Ipsen
• Kyowa Hakko Kirin Co., Ltd.
• Merck KGaA
• Nestle Health Science S.A.
• Pfizer Inc.
• PTC Therapeutics, Inc.
• Recordati S.p.A.
• Sanofi
• Shine Star Biological Engineering Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Amino Acid Metabolism Disorders Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Inborn Errors of Metabolism Spurs Demand for Targeted Amino Acid Disorder Treatments
  • Newborn Screening Mandates Throw the Spotlight on Early Diagnosis and Preventive Treatment Pathways
  • Here's How Advances in Genomic Medicine Strengthen the Business Case for Personalized Therapies and Nutritional Management
  • Expansion of Rare Disease Research Funding Globally Drives Drug Development for Urea Cycle and Organic Acidemia Disorders
  • Growing Use of Amino Acid-Based Medical Foods Expands the Addressable Market for Dietary Management Solutions
  • Here's the Story: mRNA and Gene Therapy Innovation Unlocks Long-Term Treatment Potential for Enzyme Deficiencies
  • Patient Advocacy and Rare Disease Networks Propel Awareness and Support for Expanded Access to Treatment
  • Improved Clinical Understanding of Disease Pathways Drives Development of Small Molecule and Enzyme Replacement Therapies
  • Here's How Digital Health Tools and Telemedicine Platforms Improve Monitoring and Management of Chronic Metabolic Conditions
  • Rising Focus on Quality of Life and Neurodevelopmental Outcomes Supports Holistic Treatment Approaches
  • Globalization of Clinical Trials Expands Research Pipelines for Underdiagnosed Amino Acid Metabolism Disorders
  • Growing Pediatric and Neonatal Patient Populations Sustain Long-Term Demand for Specialized Amino Acid Therapy Programs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Amino Acid Metabolism Disorders Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Amino Acid Metabolism Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Phenylketonuria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Phenylketonuria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Phenylketonuria Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Maple Syrup Urine Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Maple Syrup Urine Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Maple Syrup Urine Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Citrullinemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Citrullinemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Citrullinemia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Homocystinuria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Homocystinuria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Homocystinuria Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Argininosuccinic Aciduria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Argininosuccinic Aciduria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Argininosuccinic Aciduria Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Betaine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Betaine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Betaine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Sapropterin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Sapropterin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Sapropterin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Folic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Folic Acid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Folic Acid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Vitamin B6 & B12 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Vitamin B6 & B12 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Vitamin B6 & B12 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Arginine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Arginine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Arginine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Thiamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Thiamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Thiamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• JAPAN
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• CHINA
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: China 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• EUROPE
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• FRANCE
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: France 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: France 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: France 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• GERMANY
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Germany 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Germany 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Germany 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Italy 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Italy 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Italy 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: UK 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: UK 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: UK 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Spain 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Spain 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Spain 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Russia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Russia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Russia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Australia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Australia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Australia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• INDIA
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: India 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: India 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: India 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: South Korea 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: South Korea 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: South Korea 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Argentina 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Argentina 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Argentina 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Brazil 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Brazil 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Brazil 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Mexico 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Mexico 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Mexico 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Iran 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Iran 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Iran 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Israel 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Israel 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Israel 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: UAE 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: UAE 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: UAE 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
• AFRICA
  • Amino Acid Metabolism Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Amino Acid Metabolism Disorders Treatment by Indication - Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Africa 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Indication - Percentage Breakdown of Value Sales for Phenylketonuria Indication, Maple Syrup Urine Disease, Citrullinemia Indication, Homocystinuria Indication and Argininosuccinic Aciduria Indication for the Years 2014, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Amino Acid Metabolism Disorders Treatment by Product - Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Africa 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Product - Percentage Breakdown of Value Sales for Betaine, Sapropterin, Other Products, Folic Acid, Vitamin B6 & B12, Arginine and Thiamine for the Years 2014, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Africa 16-Year Perspective for Amino Acid Metabolism Disorders Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION